Iovance Biotherapeutics, Inc. IOVA Business Segments — Net Income Loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s business segments — net income loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s business segments — net income loss?
- Iovance Biotherapeutics, Inc. (IOVA) reported business segments — net income loss of -$79.05M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s business segments — net income loss changed year-over-year?
- Iovance Biotherapeutics, Inc.'s business segments — net income loss increased by 32.0% year-over-year, from -$116.16M to -$79.05M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s business segments — net income loss?
- Over 2 years (2023 to 2025), Iovance Biotherapeutics, Inc.'s business segments — net income loss has grown at a -6.2% compound annual growth rate (CAGR), from -$444.04M to -$390.98M.
- What does business segments — net income loss mean?
- Indicates the bottom-line financial performance of the business segment after accounting for all revenues and operating expenses. For a clinical-stage biopharmaceutical company, this metric highlights the segment's current profitability status and the extent of capital burn required to advance its therapeutic pipeline.